http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019038230-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec7aa9366c4867ba95ac5cd4fbbaec25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba3f70d4bcad1958ae8868ddab079b8f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39533 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate | 2018-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40216f3c2f9af7315fa810c8f56a7fc5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_377d5917d943a50dabafad6c04fc0a3b |
| publicationDate | 2019-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2019038230-A1 |
| titleOfInvention | SYNTHESIS VACCINE |
| abstract | The present invention relates to a combination of pharmaceutical compositions for use in the treatment or prophylaxis of a disease, having cells carrying a target antigen as a vaccine and a method of vaccinating a mammal, particularly a human, for amplifying a cellular immune response directed against cells of this mammalian recipient, particularly a human recipient, said cells expressing a target antigen. The target antigen may be, for example, an autoantigen such as a malignant antigen, i.e., a tumor specific antigen. The combination of pharmaceutical compositions comprises a first composition and a second composition, the second composition being for administration to the recipient following administration of the first composition, for example 2 to 10 days after the first composition. The combination of pharmaceutical compositions has the advantage of enhancing an effective antigen-specific T cell response against cells bearing a target antigen that may be a malignant autoantigen, e.g. to amplify a T cell response specific to the antigen. antigen against cells bearing a tumor antigen. The present invention has the further advantage of amplifying an antigen-specific T cell response in a relatively short time interval. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3986448-A4 |
| priorityDate | 2017-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 258.